Identifai Genetics raises $6.96M in ASX debut for prenatal screening platform
What's the deal? Identifai Genetics LimitedDealroom has a profile for this one. Try Dealroom → raised US$6.47M (roughly $6.96 million) in its initial public offering and joined the ASX Official List on October 9, 2026. The company issued 50,000,000 shares at US$0.13 each under a prospectus dated September 2, 2026. Trading under the ticker ID1 begins at 12:00 AEDT on Tuesday, October 13, 2026.
What's the endgame? The Western Australia-incorporated company is developing, validating, and commercially deploying WindroseTM, a genome-wide non-invasive prenatal screening platform. Proceeds from the listing fund that work.
Who's involved? Aesir Corporate Pty LimitedDealroom has a profile for this one. Try Dealroom → acted as lead manager, with no underwriter appointed. The company, based in Subiaco, has Sebastian Andre as company secretary.
Why now? At the start of trading, 108,936,320 fully paid ordinary shares will be quoted. Of those, 79,991,766 are restricted securities held in escrow until October 13, 2028, locking in major holders for two years and signalling long-term commitment from early backers.
The signal: The modest raise puts Identifai among the smaller ASX listings, betting that public capital can push a diagnostics platform from validation to commercial deployment — a path many early-stage biotech firms now take to fund the costly jump from research to market.
Read more: kalkinemedia.com
Image credit: Centers for Disease Control and Prevention
